Clinical Trials Browser

Recruiting × Myelodysplastic Syndromes × tislelizumab × Clear all

NCT06536959 2024-08-05

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Neoplasm, Residual